CN Patent

CN105848647B — 包含azd9291的药用组合物

Assigned to AstraZeneca AB · Expires 2022-04-26 · 4y expired

What this patent protects

本发明涉及适合于口服给药的药用组合物，并且更具体地涉及包括以下药用片剂组合物的药用组合物，这些药用片剂组合物包含N‑(2‑{2‑二甲基氨基乙基‑甲基氨基}‑4‑甲氧基‑5‑{[4‑(1‑甲基吲哚‑3‑基)嘧啶‑2‑基]氨基}苯基)丙‑2‑烯酰胺(“AZD9291”)或其药学上可接受的盐，其中此类组合物包括一定量的微晶纤维素和至少一种其他的药用稀释剂。

USPTO Abstract

本发明涉及适合于口服给药的药用组合物，并且更具体地涉及包括以下药用片剂组合物的药用组合物，这些药用片剂组合物包含N‑(2‑{2‑二甲基氨基乙基‑甲基氨基}‑4‑甲氧基‑5‑{[4‑(1‑甲基吲哚‑3‑基)嘧啶‑2‑基]氨基}苯基)丙‑2‑烯酰胺(“AZD9291”)或其药学上可接受的盐，其中此类组合物包括一定量的微晶纤维素和至少一种其他的药用稀释剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN105848647B
Jurisdiction
CN
Classification
—
Expires
2022-04-26
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.